Modified CEUS LI-RADS using Sonazoid for the diagnosis of hepatocellular carcinoma

Katsutoshi Sugimoto; Naohisa Kamiyama; Tatsuya Kakegawa; Hiroshi Takahashi; Takuya Wada; Masakazu Abe; Yu Yoshimasu; Hirohito Takeuchi; Takao Itoi

doi:10.14366/usg.23065

Modified CEUS LI-RADS using Sonazoid for the diagnosis of hepatocellular carcinoma

Ultrasonography. 2023 Jul;42(3):388-399. doi: 10.14366/usg.23065. Epub 2023 May 31.

Authors

Katsutoshi Sugimoto¹, Naohisa Kamiyama², Tatsuya Kakegawa¹, Hiroshi Takahashi¹, Takuya Wada¹, Masakazu Abe¹, Yu Yoshimasu¹, Hirohito Takeuchi¹, Takao Itoi¹

Affiliations

¹ Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan.
² Ultrasound Division, GE HealthCare, Hino, Tokyo, Japan.

Abstract

This review outlines several modified versions of the contrast-enhanced ultrasonography Liver Imaging Reporting and Data System (CEUS LI-RADS) that utilize Sonazoid. Furthermore, it discusses the advantages and challenges of diagnosing hepatocellular carcinoma using these guidelines, as well as the authors' expectations and opinions regarding the next CEUS LI-RADS version. It is possible that Sonazoid could be incorporated into the next version of CEUS LI-RADS.

Keywords: Contrast-enhanced ultrasound; Hepatocellular carcinoma; Kupffer cell agents; Modified CEUS LI-RADS; Sonazoid.